M&A Deal Summary |
|
---|---|
Date | 2013-08-27 |
Target | Hi-Tech Pharmacal |
Sector | Medical Products |
Buyer(s) | Akorn |
Deal Type | Add-on Acquisition |
Deal Value | 640M USD |
Advisor(s) | Nomura Investment Bank (Financial) Tashlik Goldwyn Levy ArentFox Schiff (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1971 |
Sector | Life Science |
Employees | 1,972 |
Revenue | 1.1B USD (2016) |
Akorn, Inc. is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Akorn, Inc. was founded in 1971 and is based in Lake Forest, Illinois.
DEAL STATS | # |
---|---|
Overall | 3 of 5 |
Sector (Medical Products) | 1 of 2 |
Type (Add-on Acquisition) | 3 of 4 |
State (New York) | 1 of 1 |
Country (United States) | 3 of 5 |
Year (2013) | 1 of 1 |
Size (of disclosed) | 1 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2011-03-05 |
Advanced Vision Research
Woburn, Massachusetts, United States Advanced Vision Research, Inc. (“AVR”), a ophthalmic company that develops and markets eye care products under the TheraTears® and MacuTrition ® brand names. These products are used for dry eyes, eyelid hygiene, contact lens comfort and eye nutrition. |
Buy | $26M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-04-17 |
Akorn - 4 New Drug Applications
United States Akorn - 4 New Drug Applications includes Ciprofloxacin Hydrochloride Ophthalmic Solution, Levofloxacin Ophthalmic Solution and Lidocaine Hydrochloride Jelly and one product marketed under a New Drug Application: Lidocaine/Prilocaine Topical Cream. |
Sell | - |